ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Immunomodulatory Drug (IMiD) Pregnancy: Category X — ABSOLUTELY CONTRAINDICATED in pregnancy; one exposed dose in first trimester causes fetal malformations

Thalidomide (Rheumatology / Dermatology)

Brand names: Thalidomide Celgene, Thalomid

Adult dose

Dose: 100–300 mg at night (cutaneous lupus / ENL); 50–200 mg at night (Behçet's disease)
Route: Oral
Frequency: Once daily at bedtime
Max: 400 mg/day
Mandatory participation in Thalidomide Pregnancy Prevention Programme (T-PPP/STOMPP). Women: negative pregnancy test before starting, weekly for month 1, then monthly. All patients: MANDATORY contraception. Men: use condoms during and for 1 week after stopping (semen contains thalidomide).

Paediatric dose

Route:
Not recommended in patients under 18 years — seek specialist haematology/rheumatology opinion

Dose adjustments

Renal

No dose adjustment required; thalidomide not renally cleared

Hepatic

Use with caution in severe hepatic impairment; limited data

Clinical pearls

  • MHRA/EMA: All prescriptions require enrolment in STOMPP (System of Thalidomide Oncology and Myeloma Pregnancy Prevention) — prescriptions only via enrolled pharmacies with verification of negative pregnancy test and contraception compliance
  • The thalidomide tragedy of the 1950s–60s (>10,000 neonates with phocomelia) is the defining pharmacovigilance event that led to modern drug safety regulations and the FDA 1962 Kefauver-Harris Amendment
  • Peripheral neuropathy is the most significant non-teratogenic toxicity — often irreversible and cumulative; EMG/NCS baseline and 6-monthly monitoring recommended; stop if grade 2+ sensory neuropathy develops
  • VTE risk: thalidomide + dexamethasone in myeloma has 15–30% DVT rate without prophylaxis; in rheumatology, aspirin 75–100 mg prophylaxis is standard
  • Erythema nodosum leprosum (ENL — leprosy reaction): thalidomide remains the drug of choice globally; anti-inflammatory and immunomodulatory mechanism (TNF-α inhibition)

Contraindications

  • Pregnancy — absolute contraindication; CATEGORY X
  • Women of childbearing potential not enrolled in T-PPP/STOMPP
  • Peripheral neuropathy (pre-existing)
  • Inability to comply with pregnancy prevention programme

Side effects

  • Teratogenicity — phocomelia and other congenital malformations (historical context: thalidomide disaster 1950s–60s); ABSOLUTE Category X
  • Peripheral neuropathy — often irreversible; cumulative dose-dependent; check at each visit
  • Venous thromboembolism — VTE prophylaxis required (aspirin or LMWH)
  • Sedation and somnolence — take at bedtime
  • Constipation
  • Bradycardia
  • Rash and skin toxicity

Interactions

  • CNS depressants — additive sedation
  • Other drugs causing peripheral neuropathy — additive neurotoxicity; avoid cisplatin, vincristine combination
  • Hormonal contraceptives: additional non-hormonal contraception mandatory — barrier method
  • Warfarin — possible enhanced anticoagulation

Monitoring

  • Pregnancy test before each prescription (women of childbearing potential)
  • Contraception compliance at each visit
  • Peripheral neuropathy assessment — symptoms and signs at each visit
  • FBC and LFTs
  • VTE symptoms

Reference: BNFc; BNF 90; MHRA STOMPP Programme; EMA Thalidomide Risk Management Plan; BSR Guidelines (Cutaneous Lupus); SPC Thalidomide Celgene. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways